Business
Niagen Bioscience Surpasses 300 External Research Agreements from Leading Global Institutions on Niagen®, Contributing to 45 Published Clinical Studies
LOS ANGELES, March 17, 2026--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its external research program has surpassed 300 material transfer agreements (MTAs) with investigators and research institutions around the world, marking a major milestone for what the Company believes is the most extensive dedicated NAD+ research support program in the world.
About this update from Niagen Bioscience, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2250,"height":450,"url":"https://media.zenfs.com/en/business-wire.com/e25c2f00046e3630b8b81a8e996cc5e0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ylBQ3RlFmN7AOdfGyfu8qg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5MjtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/e25c2f00046e3630b8b81a8e996cc5e0","width":960,"height":192},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/VNj2BIsIek2sjtd8N0fwQg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00ODA7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/e25c2f00046e3630b8b81a8e996cc5e0","width":1200,"height":240}},"lazy":false},{"type":"text","content":"By supporting investigator-initiated research worldwide, the program has helped establish Niagen Bioscience as a foundational force in advancing NAD+ understanding across the industry","length":183,"tagName":"p","attribs":{}},{"type":"text","content":"LOS ANGELES, March 17, 2026--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its external research program has surpassed 300 material transfer agreements (MTAs) with investigators and research institutions around the world, marking a major milestone for what the Company believes is the most extensive dedicated NAD+ research support program in the world.","length":496,"tagName":"p"},{"type":"text","content":"Rob Fried, CEO, Niagen Bioscience, commented, "Reaching more than 300 MTAs reflects the growing scientific momentum behind our patented nicotinamide riboside (NR) ingredient, Niagen®. This program has contributed to 45 published clinical studies, making Niagen the most extensively researched patented NAD-boosting ingredient in the world. Across clinical and preclinical research, Niagen has consistently been shown to elevate NAD+ safely and effectively, reinforcing the strong scientific foundation behind our ingredient."","length":535,"tagName":"p"},{"type":"text","content":"Since its founding more than eleven years ago, Niagen Bioscience’s external research program has advanced the science of Niagen and evolved into a unique, industry-leading platform for independent NAD+ research. Surpassing 300 MTAs...